Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial-Reference-Cited by-同舟云学术

Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial

Published:2005-12-07 Issue:23 Volume:97 Page:1724-1733
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Venturini Marco,Del Mastro Lucia,Aitini Enrico,Baldini Editta,Caroti Cinzia,Contu Antonio,Testore Franco,Brema Fulvio,Pronzato Paolo,Cavazzini Giovanna,Sertoli Mario Roberto,Canavese Giuseppe,Rosso Riccardo,Bruzzi Paolo

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/97/23/1724/7686871/dji398.pdf

Reference25 articles.

1. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol1997 ; 15 : 1858 –69.

2. Fisher B, Anderson S, De Cillis A, Dimitrov N, Atkins JN, Fehrenbacher L, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant breast and Bowel Project B-25. J Clin Oncol1999 ; 17 : 3374 –88.

3. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol2003 ; 21 : 976 –83.

4. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol2001 ; 19 : 602 –11.

5. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003 ; 21 : 1431 –9.

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis;Oncology Letters;2023-11-07

2. The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review;Life;2023-05-18

3. Breast cancer treatment and ovarian function;Reproductive BioMedicine Online;2023-02

4. Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience;JMA Journal;2023

5. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial;British Journal of Cancer;2022-05-24